Recently, the Stapokibart Injection (trade name: 康悦达) of Chengdu Kangnuoxing Biopharma, Inc. is approved by China NMPA. It is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis in adults who are inadequately controlled by topical medications or for whom topical medications are not indicated.

The Stapokibart Injection is a monoclonal antibody drug targeting IL-4Rα, which treats atopic dermatitis induced by excessive inflammatory response by blocking the binding of IL-4 and IL-13 to IL-4Rα receptor and inhibiting the release of downstream inflammatory factors, protein expression and inflammatory cell activity caused by IL-4 and IL-13.

The marketing of this product provides a new treatment option for adult patients with moderate-to-severe atopic dermatitis.